境外分析报告

• 马来西亚医疗器械报告2019年第一季度
  The market is the eighth largest in our Asia Pacific (APAC) region and ranks among the top 30 in the world.  Per capita spending is above average for the APAC region but close to the global average. Other medical devices has the largest market share, while the markets for dental products and orthopaedics & prosthetics remain underdeveloped. The market will see moderate growth in local currency terms and higher growth in US dollar terms due to the appreciatory trend of the MYR. Despite an expanding manufacturing industry, the market remains heavily dependent on imports in most product sectors. Malaysia is a net exporter of medical devices, due to a large trade surplus for rubber based products such as surgical gloves and catheters, and more recently other portable aids. Healthcare expenditure is near evenly split between public and private sector. The private sector is the main purchaser of high-tech equipment.
• 乔丹医疗器械报告2019年第一季度
  Tenth largest market in the Middle East & Africa (MEA) region. Per capita spending is below the MEA average. Market will record a high single-digit CAGR. Other medical devices and consumables have the largest market shares. The market is reliant on imports; the US and Germany are major partners. Local production consists largely of low technology products, such as medical dressings, syringes, dental supplies and optical products, but is not sufficient to fulfil demand. Leading medical tourism destination in the Middle East due to high quality medical services and competitive pricing. Small population but one of the fastest growing worldwide.
• 报告视网膜植入市场分析和分段预测到2026年
  Researchers are focusing on retinal prosthetics owing to relative ease of access to retina for surgery. Retina contains two types of photoreceptors: rods and cones. Presence of Retinitis Pigmentosa (RP), Age-Related Macular Degeneration (AMD), or choroideremia may increase the risk of blindness as the disease progresses. Currently, retinal implants are approved for the treatment of RP and end-stage AMD. According to Foundation Fighting Blindness, RP causes blindness in around 1.5 million people in the world. Similarly, National Eye Institute (NIE), department of National Institute of Health (NIH), states that the number of people suffering from AMD was 2.1 million in 2010 and is expected to double to reach around 5.4 million in 2050 in the U.S. The table below depicts growth of AMD patients by race
• 斯洛伐克医疗器械报告2019年第一季度
  Eighth largest market in the CEE region. Per capita spending is the fifth highest in the region. Market will record a high single-digit CAGR in local currency and US dollar terms. Consumables and orthopaedics & prosthetics have the largest market shares. The market is heavily reliant on imports in most sectors, as local manufacturing capacity is more geared to exports. Longstanding local production of dental apparatus. Comprehensive public health insurance system introduced in 1993. Relatively underdeveloped private sector.
• 报告健康信息交换市场分析和分段预测到2025年
  The healthcare systems in the majority of the countries are highly fragmented in nature, as a result of which the associated administrative costs are higher thereby creating a negative impact on the market. Clinicians and other health providers have access to limited information during point-of-care applications that may affect patient safety, which further raises the need for adoption of health information exchange.
• 卡塔尔医疗器械报告2019年第一季度
  Small but sophisticated medical device market. Imports supply most of the market. Other medical devices and diagnostic imaging have the largest market shares. High per capita spending in the Middle East Africa region. Double- digit market CAGR driven by the National Health Strategy.
• 阿曼制药与医疗保健报告2018年第4季度
  Oman's government will remain thoroughly committed to developing the country's pharmaceutical and healthcare sectors; though it is unlikely they will advance to the dominant status of neighbouring countries Saudi Arabia and the UAE. Despite a relatively attractive business environment, multinational drugmakers will prefer to opt for local contract manufacturing or importing pharmaceutical goods and will be unlikely to establish a direct manufacturing presence. As the Omani government continues to fund the majority of healthcare expenditure, private sector growth will outpace that of the public sector, owing to investment incentives and the rollout of compulsory health insurance schemes. The private sector will play a pivotal role in healthcare expansion in Oman over the long term.
• 核医学设备市场报告（2014-2222年）
  The scope of the report is limited to the revenue generated from the sales of nuclear imaging systems, also known as nuclear medicine equipment, which include SPECT and PET. SPECT and PET can be further subcategorized as standalone and hybrid systems. The standalone equipment work independently, whereas two technologies, such as PET and computed tomography (CT) or SPECT and CT, are used together for better outcomes and are known as hybrid PET and hybrid SPECT, respectively.
• 塞尔维亚医疗器械报告2019年第一季度
  Second smallest market in the CEE region. Per capita spending is well below the CEE average. Market will record moderate single-digit CAGR in local currency terms. Consumables and other medical devices have the largest market shares. Most requirements need to be imported; the US and Germany are major partners. Weak and undercapitalised domestic production sector. Relatively strong hospital sector, although the need for modernisation is great. EU negotiations began in December 2015; 12 chapters have been opened to date. 
• 医疗器械测试服务市场分析和分段预测到2025年
  The medical device testing services include biocompatibility studies, chemistry studies, microbiological & sterility testing, and package validation services. The demand for all these services is expected to rise owing to growing trend of outsourcing in preclinical and clinical phase of R&D by medical device companies.
• 医疗聚合物市场分析和分段预测到2020年
  We have segmented the study on medical polymer on the basis of product, applications and region. Medical polymers include medical resins and fibers, medical elastomers. Medical polymer applications include medical devices and equipment and medical packaging. Other applications include cardio implants and tissue engineering.
• 全球仿制药市场报告
  Generic drug markets will commoditise gradually through policies such as internal reference pricing, generic prescribing, generic substitution, and tendering. The introduction and enforcement of these guidelines will vary between countries, and are influenced by a variety of economic, political and cultural issues. Multinational manufacturers of generic drugs will therefore have to develop and employ a variety of market access strategies and operational campaigns.
• 斯洛伐克制药与医疗保健报告2019年第一季度
  Slovakia is one of the foremost Central and Eastern European (CEE) markets for innovative pharmaceutical firms seeking to expand their European revenues outside of the traditional Western Europe markets. Alongside its neighbouring countries, namely the Czech Republic, Hungary and Poland (making up the Visegrad Four), Slovakia has one of the most robust regulatory environments in the region. On the other hand, the country's small size limits the absolute size of the market. In 2017, 2.15% of the country's GDP was spent on pharmaceuticals, as combined sales of prescription drugs and OTC medicines - sold through pharmacies and hospitals at consumer prices - reached EUR1.83bn (USD2.06bn). For a Central and Eastern European country, per capita drug expenditure in Slovakia is high at USD379 in 2017, equivalent to some Western European markets and significantly higher than in some of its larger neighbours. The penetration of patented drugs in Slovakia is low compared with Western Europe. We calculate that in value terms, patented medicines represented 45.2% of the total drug market in 2017, although this remains substantially higher than the markets of the south-east and Eastern European states. Valued at EUR819mn (USD926mn), generic drugs represented 44.9% of the market, although government policies are likely to encourage growth in volumes. In the same year, OTC medicines accounted for just 9.9% of the market, at EUR181mn (USD205mn).
• 乔丹制药和医疗保健报告2019年第一季度
  The majority of Jordan's pharmaceutical production is exported to foreign markets within the Middle East. Given the limited size of Jordan's pharmaceutical market, we expect Jordan will increasingly look to develop new export partners over the coming years. The shifting disease profile towards non-communicable diseases will create further opportunities for high-value innovative drugs. However, these will remain sourced from abroad given the relatively basic nature of local drugmakers' manufacturing capabilities. In absolute terms, Jordan's pharmaceutical market is somewhat overshadowed by neighbouring countries within the Middle East. As such, Saudi Arabia and the UAE dominate pharmaceutical expenditure in the region. However, Jordan still boasts a moderately large pharmaceutical market - surpassing those of Oman, Qatar, Yemen, Bahrain and Syria.
• 柬埔寨药品和医疗保健报告2019年第一季度
  Cambodia's pharmaceutical market is underdeveloped. This, coupled with competition from neighbouring countries such as Vietnam and Thailand, means that the country is not a main focus for many multinational pharmaceutical companies looking to develop their presence in the region. In 2017, total pharmaceutical sales reached KHR1,192.4bn (USD294mn), with per capita spending reaching USD18.4. Pharmaceutical sales represent 23.7% of expenditure on healthcare and 1.3% of GDP. Total healthcare expenditure reached KHR5,034.1bn (USD1.2bn) in 2017, of which only 30% was government health expenditure and the remaining KHR3,548.3bn (USD875mn) private health spending. Per capita health expenditure reached USD77 and health expenditure represented 5.6% of GDP in 2017.
• 哥伦比亚药品和医疗保健报告2019年第一季度
  Colombia boasts one of the larger pharmaceutical markets in Latin America, though it continues to be overshadowed by still larger markets, including Mexico, Brazil and Argentina. While the government's continued commitment to health and pharmaceutical reform make the country appealing for investment, Colombia's continued battle against counterfeit medicines and troublesome intellectual property regime continue to keep it from becoming a regional outperformer.
• 土耳其药品和医疗保健报告2019年第一季度
  Turkey's pharmaceutical market is the third-largest in the Central and Eastern Europe (CEE) region, due to its considerable population size. Turkey's pharmaceutical expenditure per capita, at USD115 in 2017, is considerably lower than any EU member state. It ranks just 20th out of the 32 countries in the CEE region, trailing most markets aside from the former Soviet CIS markets.
• 南非医疗器械报告2019年第一季度
  One of the largest markets in the Middle East & Africa (MEA) region, similar in size to Iran. Market size is supported by a large population and Africa's most industrialised economy. Owing to the size of the population, per capita spending is low. Spending on medical devices as a proportion of wealth is below average for the MEA region. Other medical devices accounts for nearly 40% of the total market. Underdeveloped market offers considerable potential for growth but currently constrained by funding issues, poor infrastructure and staff shortages. National Health Insurance programme in the early stages of implementation, but question marks remain on funding and delivery of key targets. Limited medical device production, therefore market largely dependent on imports.
• 土耳其医疗器械报告2019年第一季度
  Second largest market in the CEE region. Per capita spending is below the CEE average. Slowest market growth in the CEE region, in US dollar terms. Other medical devices and consumables have the largest market shares.The market remains heavily reliant on imports. Turkey has a large number of manufacturers, but these tend to be small-scale, concentrating on cheap, low-technology items. In recent years, Turkey has focused on developing its healthcare system, with the goal of providing universal healthcare, although this is yet to be achieved. Over three quarters of total health expenditure comes from the public sector, primarily central & local governments and social security programmes.
• 疟疾诊断市场分析和分段预测到2025年
  Increasing demand for malaria diagnostics is one of the key factors driving growth of the market. Malaria is one of the most widespread life-threatening diseases, commonly occurring in the tropical and subtropical regions. Risk of malaria is more common in tropical and subtropical countries, wherein factors such as changing climate, low economic growth, underdeveloped healthcare infrastructure, and low access to advanced treatment play a vital role in disease management.